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Abstract
The development of oral tolerance or food allergy is an active process, related to dynamic interactions between
host immune cells, microbiome, dietary factors, and food allergens. Oral tolerance is the default immune response
in the gut. A food allergy occurs when this process fails and a pathologic Th2 response is activated. Oral food
immunotherapy (OIT) aims to restore immune tolerance in food-allergic individuals. The stimulation of Tregs
production seems to represent a crucial step in inducing long-term tolerance, but other mechanisms (e.g., the
suppression of mast cell and basophil reactivity, changes in allergen-specific cells with regulatory markers) are
involved. Several studies reported the efficacy of OIT in terms of "sustained unresponsiveness" (SU), an operational
definition of immune tolerance. In successfully treated subjects, the ability to pass an oral food challenge 2 to
8 weeks after stopping the food allergen exposure seems to be conditioned by the treatment starting age,
frequency, amount or type of food consumed, and by the duration of the maintenance phase. Based on the
available data, the percentage of milk- and egg-allergic subjects achieving sustained unresponsiveness after an OIT
ranges from 21% to 58,3%. A comprehensive understanding of mechanisms underlying the induction of oral
tolerance with OIT, or natural tolerance to food allergens in healthy individuals, could potentially lead to advances
in development of better treatment options for food allergic patients.
Keywords: Cow’s milk, Desensitization, Hen’s egg, Oral immunotherapy, Oral tolerance, Sustained unresponsiveness
Background
Despite increasing knowledge in oral tolerance, the
current standard of care in treating food allergy accord-
ing to the international guidelines is still a strict elimin-
ation diet [1–6]. However, the dietary approach has
several limitations. First, the risk for severe systemic re-
actions due to the presence of hidden allergens [7, 8] in
food products in spite of best efforts at strictly avoiding
food allergens. Second, avoidance diets may be associ-
ated to the risk of nutritional deficiencies and impaired
growth especially if the food/s involved represent
fundamental component of the conventional diet (such
as cow’s milk or hen’s egg) [9]. Third, inadvertent
exposure to food ingredients is an everyday risk.
Therefore, considering the increasing prevalence of food
allergy [10, 11] with a significant impact on the public
health in industrialized countries [12], attempts to mod-
ify the immune response to foods are a required choice,
particularly in severe food allergies [13]. Oral immuno-
therapy (OIT) aims to do so through food exposure.
The first report of successful desensitization per-
formed in a hen’s egg allergic patient dates back to 1908
[14], and until the end of the 1990s only a few sporadic
cases were reported [15, 16]. The use of subcutaneous
route was related to high-risk of severe systemic reac-
tions [17, 18] and was quickly abandoned. Starting from
the end of the twentieth Century, an increasing number
of OIT studies was reported in the literature. In addition
to case reports [19, 20], clinical trials on OIT as an ef-
fective treatment for food allergy began to be published* Correspondence: valentina.pecora@opbg.net
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[21–24]. A hundred years after the first report, inter-
national scientific societies became interested in OIT.
With the resulting exponential increase in the number
of clinical trials published, metanalyses became possible
[25–29]. Their current evidence suggests a proved effi-
cacy in short-term tolerance, while information on long-
term outcomes is limited and mostly focused on milk
OIT. The long-term follow-up studies [30–33] have pro-
posed to evaluate only the regular intake of the incrimi-
nated food, sometimes reporting adverse reactions
occurred during the follow-up period. Side effects com-
monly reported in the literature are the main weakness
of this treatment, which is still not recommended in the
routine clinical practice. Generally, most reactions aris-
ing from clinical trials are mild and limited to the oro-
pharynx resolving without intervention or with
antihistamine alone. However, systemic or severe reac-
tions do not seem unlikely and are most frequent during
the build-up phase commonly conducted under phys-
ician supervision.
Oral tolerance to food protein in the gut
The gastrointestinal tract is the major route of exposure
to food allergens and the largest reservoir of immune cells
in the body. Intestinal commensal bacteria induce protect-
ive and regulatory responses that maintain host-microbial
mutualism, and the mucosal immune system plays a cru-
cial role protecting the gastrointestinal tract from invading
pathogens and keeping the commensal microbiota com-
partmentalized. The epithelial cells, responsible for separ-
ating the mucosal immune system from the gut lumen,
secrete a number of factors that contribute to barrier func-
tion, including mucins, antimicrobial peptides, and trefoil
factors. This type of cells also transport antibodies, par-
ticularly IgA, into the intestinal lumen where these anti-
bodies can contribute to barrier function by excluding the
uptake of antigens or microbes [34]. The resident immune
cells, located inside the matrix of the Peyer’s patches, in-
clude CD4+ and CD8+ T effector and regulatory T cells
(Tregs), B cells, macrophages and dendritic cells. The latter
in particular are critical for maintaining immune
homeostasis within the gut. Their major functions
concern the processing and the presentation of antigens, a
critical step in the activation of T cells. In detail, CD103+
dendritic cells in the mesenteric lymph nodes express high
levels of the enzyme retinal dehydrogenase 2 (RALDH2),
which converts retinal to retinoic acid promoting gut-
homing activity and development of Tregs from naïve T
cells as well as secretion of transforming growth factor β
(TGF-β) [35, 36].
Gut-associated intestinal lymphoid tissue discriminates
between potentially harmful pathogens and non-harmful
antigens. Therefore, it is possible to observe an activa-
tion of a protective immune response or an ‘off ’ state of
T cell due to a functionally inactivation of lymphocyte
following an antigen encounter, such as food or com-
mensal bacteria [34].
The intestinal microbiota varies between individuals,
and plays key roles in defense against pathogens as well
as food digestion and nutrition. In case of dietary
changes, a modification in bacterial metabolites (such as
short-chain fatty acids that derive from fermentation of
dietary fibers) is observed, with repercussions on muco-
sal integrity and inflammasome activation [37]. The
inflammasome pathway and production of the cytokine
interleukin (IL)-18 are critical for intestinal homeostasis
and epithelial integrity by ensuring repair and cell sur-
vival under stress conditions [38, 39].
Immunomodulation during a specific food allergen
immunotherapy
The goal of food immunotherapy (oral, sublingual or epi-
cutaneous) is to modify the immune response towards
food protein antigens. Many studies report suppression of
mast cell and basophil reactivity, a reduction of allergen-
specific IgE and a simultaneous increase of allergen-
specific IgG4 antibodies [40, 41]. At the same time, the
interest of researchers was focused on Tregs, and specific-
ally on two different populations: CD4 + CD25+ forkhead
box P3 (Foxp3)+ Treg cells and Th3 cells. The inhibitory
cytokine TGF-β is responsible for the mechanism of sup-
pression provided by Th3 cells expressing a late-stage
Treg activation marker, latency associated peptide (LAP),
which forms a complex with TGF-β [42, 43]. Based on the
recent evidences [41], Foxp3+ Tregs were induced by the
three treatment routes but in particular by epicutaneous
immunotherapy (EPIT). LAP+ Treg levels increase in EPIT
and OIT, whereas IL-10+ cells are induced by sublingual
immunotherapy (SLIT). The suppressive activity of EPIT-
induced Tregs required cytotoxic T-lymphocyte antigen 4
(CTLA-4), whereas SLIT is strictly dependent on IL-10
and OIT acted through both mechanisms. IL-10 repre-
sents a key cytokine inhibiting INF-γ and IL-2 secretion
by Th1 cells and IL-4/IL-5 production by Th2 cells. The
stimulation of Treg production seems to represent a
crucial step in inducing long-term tolerance. A boosting
of antigen-specific serum IgA level was observed in a
mouse model of food OIT [44]. In this case the
neutralization by allergen-specific IgA would demonstrate
a protective role. In addition, according to the murine
model the OIT protection would be localized to the
gastrointestinal tract with significant downregulation of
gastrointestinal gene expression [44].
Could OIT be conceived of as a disease-modifying
treatment?
Until a few years ago, the possibility that OIT could be
able to modify the natural history of food allergy was
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not expected. Many studies indicated that the mainten-
ance of tolerance status obtained with the OIT required
constant exposure to the food allergen [23, 45–47]. In
2012 the term “sustained unresponsiveness” (SU) was in-
troduced for the first time [48], describing the ability of
a food allergic subject, successfully desensitized with
OIT, to pass an oral food challenge (OFC) conducted
generally 28 weeks after stopping the food allergen ex-
posure. Patients getting SU from their OIT will be
allowed to introduce a previously allergenic food into
their diet ad libitum, as happens to subjects who spon-
taneously acquire a clinical tolerance.
During the last 5 years, several clinical studies have
been proposed to demonstrate the achievement of a SU
in food allergic patients. Currently available data concern
patients with cow’s milk, hen’s egg and peanut allergy.
Considering that children allergic to milk and egg are
most likely going to outgrow spontaneously their food
allergies, all available data must be critically reviewed. In
this regard, the age of enrollment should not be under-
estimated. All clinical trials [36, 49–54] published on SU
achieved after an OIT with cow’s milk and hen’s egg are
expected to enroll food allergic subjects aged over 5 years
(Table 1). Different dosing schedules and varying dura-
tions in terms of maintenance phase and food avoidance
period also make comparison between trials difficult.
Based on the available data, the percentage of milk- and
egg-allergic subjects achieved SU after an OIT ranges
from 21% to 58,3% in a few years.
Egg
Burks and colleagues [48, 51] published their experience
with OIT in egg allergic individuals by analyzing the re-
sults obtained at 2 and 4 years from the beginning of the
research protocol. The goal was to desensitize the sub-
jects to 2 g of egg-white powder, achieved by just under
50% (18/40) of subjects randomized to the active pro-
cedure group within the first 10 months. At 10 months
and 22 months, all participants underwent an OFC con-
sisting of 5 g and 10 g (cumulative dose) of egg-white
powder respectively. At 22 months, 30 of 40 children
(75%) in the OIT group successfully passed the chal-
lenge, discontinued OIT and avoided all egg consump-
tion for 4 to 6 weeks. At 24 months, these children
underwent an OFC with 10 g of egg-white powder to
test for sustained unresponsiveness and 11 (27.5%) suc-
cessfully passed the challenge (P = 0.03, as compared
with placebo) with the resulting instruction to add egg
to their diet ad libitum without specific recommendation
on frequency, amount, or type of egg product. Consider-
ing the immune markers measured, small wheal diame-
ters on skin-prick testing and increases in egg-specific
IgG4 antibody levels were associated with passing the
oral food challenge at 24 months. At a later point of
time, the authors evaluated the efficacy and safety of egg
OIT in the same participants treated up to 4 years [51].
Long-term follow-up questionnaires were administered
after study conclusion (LFQ-1) and 1 year later (LFQ-2)
to assess possible effects of the lifestyle on the outcomes
of the study. At Years 3 and 4, all subjects treated with
egg OIT underwent a 10 g (cumulative dose) OFC to
egg white powder to assess desensitization. Those who
passed the desensitization OFC discontinued OIT dosing
for 4–6 weeks and had a second OFC (10 g as a cumula-
tive dose), to assess for SU. At the fourth year of treat-
ment, the percentage of patients who achieved SU rose
to 50% (20/40). During both LFQ periods, the egg OIT–
SU group showed a greater consumption of unbaked
and baked egg in terms of frequency and amount com-
pared to egg OIT-desensitized group. At year 4, subjects
achieving SU had higher IgG4 values (p = 0.001) and
lower egg skin prick test scores (p = 0.0002) over time
and a lower median baseline ratio of egg-specific IgE to
total IgE (1.1% vs. 2.7%, p = 0.04).
Recently, a 71% (15/21) SU to egg was reported 2
weeks after the discontinuation of a low-dose (1/32 egg)
OIT, carried out for 12 months [50].
The efficacy of a short-course egg OIT to induce SU was
also reported. Thirty-seven per cent of patients (11/30)
passed an OFC performed at 4 months after a 30-day
avoidance period [49]. These tolerance rates clearly exceed
those expected from the natural history of egg allergy
resolution. If these data will be confirmed, OIT should be
considered a disease-modifying treatment in egg allergy.
Milk
A milk OIT, supported by the simultaneous use of omali-
zumab, was also reported to be associated with SU [53].
At month-28, omalizumab was discontinued and subjects
passing an OFC continued OIT for 8 weeks, after which
OIT was discontinued with re-challenge at month-32. SU
was demonstrated in 13/27 (48.1%) of the active group.
Afterwards, the authors sought to investigate mechanisms
by which omalizumab modulates immunity in the context
of OIT and to identify baseline biomarkers that predict
subgroups of patients most likely to benefit from
omalizumab [55]. A reduction of milk-induced basophil
CD63+ expression was observed in omalizumab- and
placebo-treated subjects. However, IgE dependent hista-
mine release increased in washed cell preparations only
from omalizumab-treated subjects. Baseline basophil
CD63+ expression was strongly associated with the
occurrence of symptoms during OIT. The degree of
suppression in milk-induced CD63+ expression at months
28 and 32 was associated with the likelihood of passing an
OFC at these visits, suggesting that inhibition of basophil
reactivity might be central to the underlying mechanisms
responsible for desensitization to milk. The combination
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Table 1 Characteristics and results of hen’s egg and cow’s milk OIT RCTs
Egg Burks et al. (2012) Escudero et al. (2015) Yanagida et al. (2016) Jones et al. (2016)
Study design RCT double blinded RCT, not blinded RCT, not blinded RCT, follow-up
Age range (years) 5–11 (median age: 7 ys) 5–17 (median age: 8 ys) ≥5 5–11 (median age: 7 ys)
Number of patients
(active group)
40 30 21 40
Number of patients
(control group)
15 31 12 15
Withdrew from therapy
(active group)
5 2 5 5
Withdrew from therapy
(control group)
2 0 0 2
OIT duration 22 months 3 months 10 weeks 48 months
Maximum tolerated dose 2 g one undercooked egg
every 2 days
62–194 mg 2 g
DBPCFC after OIT in
placebo group
At month 10 (5 g) 100% positive Not performed Not performed Not performed
DBPCFC after OIT in
active group
At month 10 22 negative (55%) (P < 0.001)
At month 22 (10 g) 30 negative (75%)
(P < 0.001)
Not performed Not performed Not performed
Time of elimination
diet (weeks)
4–6 4 2 4–6
DBPCFC after
food avoidance
(cumulative maximum dose)
At month 24 (10 g)
11 negative
At month 4 (3,6 g)
1 negative in CG
11 negative in AG
At week 12 (3 g)
0 negative in CG
7 negative in AG
At month 36
18 negative
At month 48
20 negative
Sustained unresponsiveness (%) 28 (P = 0.03) 37 33,3 (P = 0.032) 45% at year 3
50% at year 4
Milk Yanagida et al. (2015) Wood et al. (2016) Takahashi et al. (2016)
Study design RCT, not blinded RCT, double blinded RCT, not blinded
Age range (years) ≥5 7–35
AG median
11.7 years
CG median 9.5 years
5–17
AG median 9 years
CG median 7 years
Number of patients
(active group)
12 28 (OIT plus
omalizumab)
31
Number of patients
(placebo group)
25 29(OIT plus placebo) 17
Withdrew from therapy
(active group)
0 2 0 at year 1
11 at year 4
Withdrew from therapy
(placebo group)
0 5 0
OIT duration 12 months 30 months 4 years
Maximum tolerated dose 3 ml 3.8 g 200 ml
DBPCFC after OIT in
placebo group
4 negative (3 ml) 20 negative (10 g) 0 negative (80 ml)
DBPCFC after OIT in
active group
9 negative (3 ml) 24 negative (10 g) 14 negative (80 ml)
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of baseline basophil and serologic biomarkers allowed to
define a subset of patients in which adjunctive therapy
with omalizumab was associated with attainment of SU
and a reduction in adverse reactions. Neither omalizumab-
nor placebo-treated subjects exhibited a significant in-
crease in the percentage of casein-specific Treg cells over
the course of treatment.
The duration of maintenance phase appears to have a
decisive influence on the achievement of SU in cow’s
milk allergic subjects. To this end, a Japanese study
demonstrated that, 2 years after the start of OIT, the rate
of 2-weeks-SU in the active group significantly increased
compared with the rates at 1 year (P = 0.008) [54].
There are many considerations to be made regarding
the factors that might affect the achievement of a SU in
food allergic subjects after an OIT. First, the age bias
could represent a decisive variable and future studies
should investigate whether treatment outcomes regard-
ing desensitization or SU are influenced by OIT’s start-
ing age. Second, the analysis of microbiome of food
allergic subjects before and after OIT could provide
useful information regarding the achievement of
desensitization or SU [56]. Third, clinical tolerance in-
duced by food immunotherapy is associated with
changes in basophils, IgG4, allergen-specific Th2 cells,
and allergen-specific cells with regulatory markers. The
identification of significant changes from the baseline,
correlated with SU, would be helpful to provide the ne-
cessary dietary information to patients. Unlike SU, the
state of desensitization requires to continue a regular al-
lergen intake indispensable to maintain the established
tolerance. Forth, the food habits in terms of frequency,
amount, or type of food product consumed (unbaked
and baked) seem to directly influence the achievement
of SU. Fifth, long-term follow-up studies on OIT will
allow to obtain a global view with the consequence of
identifying possible factors likely to predispose food
allergic subjects to achievement SU.
Conclusion
Despite a growing knowledge about the pathophysio-
logic mechanisms underlying allergic diseases, immune
responses associated with tolerance still need investiga-
tion. Oral tolerance represents an active regulatory
immune response. The mechanisms inducing oral toler-
ance are manifold and involve allergen-specific Treg
cells generated by mucosal DC, intestinal mucins and
cytokines coming from epithelial cells and innate
lymphoid cells. Gut-associated intestinal lymphoid tis-
sue discriminates between potentially harmful patho-
gens and non-harmful antigens, with a consequent
functional inactivation of lymphocyte following ad anti-
gen encounter (such as food or commensal bacteria). In
addition, integrity of mucosal epithelial barrier and in-
testinal homeostasis are influenced by the inflamma-
some pathway and production of IL-18 [34, 35]. As for
humoral mechanisms, the detection of allergen-specific
IgG4 is especially associated with a clinical tolerance to
foods. However, it is not clear if they represent an
active mechanism of immune tolerance or a mere con-
sequence of food exposure in subjects consuming aller-
genic foods.
Important assessments to be consider before starting
an OIT include the type of offending food/s and the age
of allergic subjects. Indeed, at least 80% of milk- and
egg-allergic children are expected to achieve spontan-
eous clinical tolerance by the school age, whereas the
percentage falls to 10–20% in the case of peanut- or tree
nut–allergic subjects [57, 58]. For this reason, the OIT’s
starting age is crucial to achieve reliable results espe-
cially in the case of milk or egg allergic patients.
The spontaneous resolution of food allergy in children
is associated with an increased frequency of peripheral
blood CD4+ CD25+ Tregs after an OFC and a reduced
proliferation of food allergen specific T cells [59, 60].
The depletion of CD4+ CD25+ Tregs restores the in vitro
proliferative response in food allergen tolerant
individuals [53].
The literature data certainly support the hypothesis
that the OIT is able to accelerate the resolution of food
allergy. Indeed, this type of treatment aims to re-
introduce safely the offending food into the diet in a
relatively short time. The OIT is associated with a
suppression of mast cell and basophil reactivity, with a
consequent reduction of allergen-specific IgE and simul-
taneous increase of allergen-specific IgG4 antibodies.
Subjects successfully treated with OIT showed changes
in allergen-specific cells with regulatory markers, in
Table 1 Characteristics and results of hen’s egg and cow’s milk OIT RCTs (Continued)
Time of elimination
diet (weeks)
2 8 2
DBPCFC after food avoidance
(cumulative maximum dose)
At month 12.5 (3 ml)
4 negative in CG
7 negative in AG
At month 12.5 (25 ml)
0 negative in CG
4 negative in AG
At month 32 (10 g)
10 negative in CG
13 negative in AG
At year 1 (80 ml)
7 negative/31
At year 2 (80 ml)
14 negative/30
Sustained unresponsiveness (%) 58.3%
P = 0.018
33.3%
P = 0.007
35.7% in CG
48.1% in AG
At year 1 21%
At year 2 47%
P = 0.008
Pecora et al. World Allergy Organization Journal  (2018) 11:11 Page 5 of 7
particular Foxp3+ and LAP+ Tregs, which seem to play a
central role in inducing long-term tolerance. The lack of
acquisition regarding the SU in all treated patients un-
derlies significant differences in individual immune re-
sponse. In this context, emphasis should be placed on a
more comprehensive understanding of mechanisms
underlying the induction of oral tolerance with immuno-
therapy or natural tolerance to food allergens in healthy
individuals, to enable the development of better treat-
ment options for food allergic patients.
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